Kythera Biopharma Says Top-Line Phase III Trial Results for ATX-101 Met Primary, Secondary Endpoints

KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH ) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm^2 dose of ATX-101 versus placebo for the reduction